Clinical trials: Diabetic Nephropathy
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Diabetic Nephropathies
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
The main objective of this trial is the safety and tolerability of 3 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme…
- Trial name
- NCT03165227
- Testing
- BI 685509
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic…
- Trial name
- NCT06489340
- Testing
- 2HPβCD
- Where
- United States
- Sponsor
- ZyVersa Therapeutics, Inc.
Diabetic Nephropathy
A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
The efficacy and safety of Cilostazol and Probucol in combination on patients with diabetic nephropathy is better than the single use.
- Trial name
- NCT01252056
- Testing
- Probucol, Probucol and Cilostazol
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Otsuka Beijing Research Institute
Diabetic Nephropathy
An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
This study aims to evaluate the safety and efficacy of MT-3995 administered over the longer term, following MT-3995-J05 study.
- Trial name
- NCT02676401
- Testing
- MT-3995 Low, MT-3995 Middle, MT-3995 High
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- Tanabe Pharma Corporation
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes, Hypertension
Real-world Aliskiren Use in Diabetic Patients
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
- Trial name
- NCT01393860
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Kidney Diseases, Diabetic Nephropathies
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change…
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid
- Trial name
- NCT04387448
- Testing
- GFB-887
- Where
- 74 sites in United States
- Volunteers
- 96 people
- Sponsor
- Goldfinch Bio, Inc.